San Diego-based medical device company DexCom, Inc. is making strides in the design and commercialization of continuous glucose monitoring (CGM) systems, aimed at diabetes management. Its products, including the Dexcom G6 and G7, offer integrated CGM systems for diabetes patients, as well as Dexcom Share, a remote monitoring system, and Dexcom Real-Time API, which allows third-party software developers to integrate real-time CGM data into their apps and devices for specific and permitted use cases. DexCom, Inc. also offers Dexcom ONE, designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company markets its products directly to endocrinologists, physicians and diabetes educators, and boasts a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. Founded in 1999, DexCom, Inc. continues its goal to improve diabetes management with innovative CGM solutions.